The trial is a phase 1/2 study for Vertex’s VX-880, an insulin-producing therapy being tested among diabetes patients with hypoglycemia, according to a Jan. 7 news release. Seventeen participants were enrolled in the study, according to clinicaltrials.gov, but one patient withdrew consent from the study, the release said.
All 14 patients who received VX-880 “demonstrated islet cell engraftment and production of endogenous insulin,” Vertex said.
“Two patient deaths, both unrelated to VX-880, have occurred,” the drugmaker said. “Vertex has placed the study on a protocol-specified pause, pending review of the totality of the data by the independent data monitoring committee and global regulators.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
